肺癌患者血清中新型肿瘤标志物CK18-3A9检测的临床意义

The detection of a new tumor marker CK18-3A9 in serum of lung cancer patients

目的评价一种新型的血清肿瘤标志物CK18-3A9在肺癌辅助诊断和疗效评估中的临床应用价值。方法应用化学发光法检测100例肺部良性疾病患者和100名正常人血清中CK18-3A9的水平以及165例肺癌患者化疗前和化疗后1个周期血清中CK18-3A9的水平。结果肺癌患者血清中CK18-3A9的水平均明显高于肺部良性疾病组和正常人组(P<0.01);CK18-3A9在腺癌中的水平和敏感性明显高于其他类型的肺癌(P<0.05);CK18-3A9在Ⅲ期+Ⅳ期中的水平明显高于Ⅰ期+Ⅱ期(P<0.05)。疾病进展患者化疗1个周期后CK18-3A9的水平明显升高(P<0.01);疾病稳定和部分缓解患者化疗1个周期后CK18-3A9的水平明显下降(P<0.01)。结论新型肿瘤标志物CK18-3A9的检测对于肺癌的辅助诊断和鉴别诊断有一定的临床应用价值,CK18-3A9可作为一种肺癌化疗疗效评价参考指标,值得在临床上推广使用。

Objective To evaluate a new type of tumor biomarker cytokeratin(CK)18-3A9 in serum for the diagnosis as well as assessment of treatments of lung cancer.Methods The serum CK18-3A9 levels were examined by chemoilluminence method in 100 patients with non-malignant lung diseases and 100 cases from the healthy population,as well as 165 cases of lung cancer patients prior to chemotherapy,and after one treatment course.Results The level of CK18-3A9 in patients with lung cancer was higher than that of patients with respiratory infection of the lung and controls(P<0.01).The level of CK18-3A9 in patients with adenocarcinoma was higher than that of other subtypes of the lung cancer(P<0.01)whereas CK18-3A9 was found to be higher in stages Ⅲ and Ⅳ than stages Ⅰ and Ⅱ(P<0.05).Serum CK18-3A9 levels for patients with cancer progression were found to increase after one course of chemotherapy(P<0.01)whereas patients with stabilized tumorigenesis or tumor regression showed a significant trend of CK18-3A9 decrease(P<0.01).Conclusions Detection of new tumor biomarker CK18-3A9 has certain clinical values for diagnosis and verification of diagnosis.CK18-3A9 can be deployed as a new type of effective parameter for evaluating efficacy of chemotherapy of lung cancer.